Beryl is developing a patented first-in-class small molecule to increase peak bone mass and cure poor bone mineral density.
Beryl Therapeutics has raised $250K in total funding. The most recent round was Grant. The last funding was announced in May 2023.
Beryl Therapeutics's investors include Advanced Industries Accelerator (AIA) Program, The Foundation for Prader-Willi Research.
Beryl Therapeutics is headquartered in Longmont, United States.
Beryl is developing a patented first-in-class small molecule to increase peak bone mass and cure poor bone mineral density.
Beryl Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Beryl Therapeutics — Funding & Investors." VCBacked, May 18, 2023, https://www.vcbacked.co/company/beryl-therapeutics. Accessed July 25, 2026.
VCBacked. (2023). Beryl Therapeutics — Funding & Investors. Retrieved July 25, 2026, from https://www.vcbacked.co/company/beryl-therapeutics
{{cite web |title=Beryl Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/beryl-therapeutics |website=VCBacked |access-date=July 25, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated